{
  "docId": "019de076-48c2-7315-bf77-72d2721572a4",
  "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91",
  "documentTitle": "Immatics | Investor Presentation Deck | 75 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 74,
  "pageCount": 75,
  "prevPage": 73,
  "nextPage": 75,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 60,
  "notes": "Data cut-off Sep 30, 2023. N=28 patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/74",
  "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4",
  "deckJsonHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4.json",
  "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-74",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.32,
        "x": 0.32,
        "y": 0.54
      },
      "kind": "disclaimer",
      "text": "All treatment-emergent adverse events (TEAEs) with ≥ Grade 3 regardless of relatedness...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d24b76b-cc6a-4502-93c6-a418c89e875c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.66,
        "y": 0.295
      },
      "kind": "list",
      "text": "IMA203 was well tolerated at doses as high as ~10x10^9 TCR-T cells; Most frequent ≥Grade 3 AEs were expected cytopenia associated with lymphodepletion; No IMA203-related Grade 5 AEs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38b32042-8cb2-42b8-a441-38b5b81aaf51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.6,
        "x": 0.04,
        "y": 0.225
      },
      "kind": "table",
      "text": "TEAEs by maximum severity for all patients in Ph1a dose escalation DL4 and Ph1b Cohort A dose expansion (RP2D, N=28)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "644ee2b7-da20-42aa-b926-e708eed85c90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "IMA203 GEN1 at RP2D – Tolerability Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fd0f810-1d62-453b-bdd8-ae1a3495bd8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "Phase 1a DL4 and Cohort A – All ≥Grade 3 Adverse Events (N=28)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fe1ef0e-73cb-4216-be13-597e90c4d5fd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}